These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33419717)

  • 1. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
    Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
    Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
    Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
    Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
    Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Dittus C; Grover N; Ellsworth S; Tan X; Park SI
    Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
    Ramirez-Gamero A; Martínez-Cordero H; Beltrán BE; Florindez J; Malpica L; Castillo JJ
    Am J Hematol; 2024 Aug; 99(8):1586-1594. PubMed ID: 38767403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
    Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
    Liu M; Liu B; Liu B; Wang Q; Ding L; Xia C; Dong L
    Oncol Rep; 2015 Apr; 33(4):1615-20. PubMed ID: 25695332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
    Feng J; Xu L; Dong HJ; Zhang N; Bai QX; Liang R; Shu MM; Yang L; Chen XQ; Gu HT; Gao GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1350-1354. PubMed ID: 30295249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
    Jessa R; Chien N; Villa D; Freeman CL; Slack GW; Savage KJ; Scott DW; Sehn LH; Song KW; Gerrie AS
    Br J Haematol; 2022 Oct; 199(2):230-238. PubMed ID: 35961783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
    Rapiti N; Peer N; Abdelatif N; Rapiti P; Moosa Y
    HIV Med; 2022 Sep; 23(8):837-848. PubMed ID: 35229978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
    Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
    J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
    Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
    AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
    Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin G; Butera JN
    Oncologist; 2010; 15(3):293-9. PubMed ID: 20167839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
    Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
    Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
    Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
    Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.